2022
DOI: 10.1016/j.jsat.2022.108776
|View full text |Cite
|
Sign up to set email alerts
|

Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 53 publications
0
3
0
Order By: Relevance
“…The introduction of long‐acting injectable buprenorphine (LAIB) preparations has changed the treatment landscape for opioid use disorder, allowing consumers to undergo opioid substitution therapy that is tailored to their individual circumstances and having a positive impact on individual social determinants of health (Martin et al, 2022). As a treatment for opioid use disorder, LAIB is typically used as a monthly injection administered by a qualified clinician, and several studies have shown improved treatment retention and access through using this preparation to treat opioid use disorder (Andrada et al, 2022; Lofwall & Fanucchi, 2021).…”
Section: Introductionmentioning
confidence: 99%
“…The introduction of long‐acting injectable buprenorphine (LAIB) preparations has changed the treatment landscape for opioid use disorder, allowing consumers to undergo opioid substitution therapy that is tailored to their individual circumstances and having a positive impact on individual social determinants of health (Martin et al, 2022). As a treatment for opioid use disorder, LAIB is typically used as a monthly injection administered by a qualified clinician, and several studies have shown improved treatment retention and access through using this preparation to treat opioid use disorder (Andrada et al, 2022; Lofwall & Fanucchi, 2021).…”
Section: Introductionmentioning
confidence: 99%
“…LAIBs have been shown overall to positively impact on the social determinants of health. 9 This case series explores direct induction onto high-dose Buvidal Weekly 24 mg or 32 mg or Buvidal Monthly 128 mg without prior stabilisation on either sublingual buprenorphine or lower-strength Buvidal Weekly preparations.…”
mentioning
confidence: 99%
“…OST prescribing is typically the remit of general practitioners (GPs), however research has identified an ageing cohort of prescribers and several barriers to new GPs taking on this work (Longman et al, 2011(Longman et al, , 2012. Further, the introduction of the long-acting injectable buprenorphine preparation has become a mainstay of treatment for opioid dependence (Barnett et al, 2021;Martin et al, 2022), and specialist AOD treatment roles have moved into areas beyond what would be considered 'traditional' treatment settings, such as emergency departments and community health services; many health services have moved to this model of care to implement wider screening and brief intervention, particularly for alcohol use (Nordeck et al, 2018;Reeve et al, 2016).…”
mentioning
confidence: 99%